5 Revealing Analyst Questions From Cencora's Q4 Earnings Call

Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncology acquisition as pivotal to driving both revenue and operating income growth. The quarter was also shaped by strong sales of GLP-1 medications and the company’s ongoing focus on supporting specialty care providers.

Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Cencora’s Q4 Earnings Call

• Glen Santangelo (Barclays) pressed management on the deceleration in U.S. segment operating income growth and its sustainability. CFO James Cleary explained that, excluding certain acquisitions and customer losses, core performance remains within the long-term guidance range due to solid specialty utilization trends.
• Elizabeth Anderson (Evercore ISI) asked about short- and long-term growth drivers from the MSO platform. CEO Robert Mauch pointed to immediate opportunities in leveraging clinical trial excellence and revenue cycle management, with future gains expected from new physician-focused services.
• Lisa Gill (JPMorgan) inquired about growth opportunities with health systems. Mauch highlighted tailored partnerships and Cencora’s aim to be the provider of choice for specialty care across both health systems and physician practices.
• Michael Cherny (Leerink Partners) questioned the impact of recent drug price negotiations and related supplier contracts. Cleary stated that strong sourcing capabilities allowed Cencora to maintain gross profit dollars, with no material impact from recent price changes.
• Kevin Caliendo (UBS) explored the company’s appetite for asset divestitures and their potential impact on growth. Mauch and Cleary reiterated a strategy focused on growth-aligned investments, acknowledging that some divestitures could be dilutive in the short term but are expected to benefit long-term growth rates.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team is monitoring (1) how effectively Cencora integrates and scales its MSO acquisitions to drive specialty platform synergies, (2) the extent of operating income improvement in international markets as timing headwinds recede, and (3) the company’s progress on realigning its business portfolio for long-term growth. Continued execution in specialty pharmaceuticals and the ability to manage financing costs will also be important signposts.

Cencora currently trades at $360.65, in line with $361.75 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.